Anteris to Present at Healthcare Investor Conferences TD Cowen and Barclays
Rhea-AI Summary
Anteris (NASDAQ: AVR) announced that CEO Wayne Paterson will present at two investor conferences in March 2026: TD Cowen on March 2, 2026 and Barclays on March 10, 2026. Both appearances include fireside chats and 1x1 meetings with webcasts available.
Webcast links and replays (archived for up to 90 days) are available via the company investor presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – AVR
In the Feb 23 session, AVR gained 8.45%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-01-22 | Strategic investment | Positive | -1.7% | Medtronic completes $90M strategic investment within larger $320M capital raise. |
| 2026-01-22 | Equity offering close | Negative | -1.7% | Closing of $230M public offering plus Medtronic private placement at $5.75. |
| 2026-01-20 | Offering pricing | Positive | +12.5% | Pricing of $200M public offering with planned Medtronic private placement. |
| 2026-01-20 | Proposed financing | Positive | +12.5% | Announcement of proposed $200M offering and up to $90M Medtronic investment. |
| 2025-11-17 | Clinical data update | Positive | -3.3% | DurAVR THV 30-day outcomes in 100 patients presented at PCR London Valves. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: positive financing and strategic announcements sometimes produced strong gains, while other seemingly positive strategic or clinical updates saw shares trade lower, indicating inconsistent alignment between news tone and price moves.
Over the last few months, Anteris has focused on major financings and strategic partnerships. In January 2026, it announced a proposed and then priced $200 million offering with a potential $90 million Medtronic private placement, which coincided with a 12.52% gain. The subsequent closing of the $230 million public offering and Medtronic’s $90 million strategic investment on Jan 22, 2026 saw a modest -1.67% move. Earlier, positive DurAVR THV clinical data for 100 patients in November 2025 coincided with a -3.25% reaction. Today’s conference participation fits into ongoing investor-relations and visibility efforts rather than a new financial or clinical inflection point.
Key Terms
structural heart medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS and BRISBANE, Australia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, is pleased to advise that Vice Chairman and Chief Executive Officer, Wayne Paterson will be presenting at both the TD Cowen 46th Annual Healthcare Conference and the Barclays 28th Annual Healthcare Conference.
The details of each conference and how to access them are as follows:
TD Cowen 46th Annual Healthcare Conference
| Date: | Monday, March 2nd, 2026 (US time) |
| Format: | Fireside chat with analyst, Joshua Jennings, and 1x1 meetings |
| Time: | 3:10-3:40PM (US EST) |
| Room: | Provincetown, 4th Floor |
| Location: | Marriott Copley Plaza, Boston, MA |
| Webcast link: | https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/VqMTEJXfhDZmYysHqmpCsL |
Barclays 28th Annual Healthcare Conference
| Date: | Tuesday, March 10th, 2026 (US time) |
| Format: | Fireside chat with analyst, Matt Miksic, and 1x1 meetings |
| Time: | 1:30-1:55PM (US EST) |
| Room: | Americana 2 (Track 2) |
| Location: | Loews Miami Beach Hotel, Miami Beach, FL |
| Webcast link: | https://cc.webcasts.com/barc002/031026a_js/?entity=65_NQYO8PJ |
The webcasts of the TD Cowen and Barclays fireside chats can be accessed by visiting the Investor Center section of the Company’s website at https://anteristech.com/investors/investor-presentations.html. A replay of the webcast will be archived for up to 90 days.
About Anteris
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (“THV”), was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System.
Forward-Looking Statements
This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
| For more information: | ||
| Global Investor Relations | Investor Relations (US) | |
| investors@anteristech.com | mchatterjee@bplifescience.com | |
| Debbie Ormsby | Malini Chatterjee, Ph.D. | |
| Anteris Technologies Global Corp. | Blueprint Life Science Group | |
| +61 1300 550 310 | +61 7 3152 3200 | +1 917 330 4269 |
Website www.anteristech.com
X @AnterisTech
LinkedIn https://www.linkedin.com/company/anteristech
